EvolveImmune develops immuno-oncology biologics that provide sustained immune activation while directly targeting tumor cells within a single drug. The company integrates signaling to enable its EVs platform to directly target tumor cells and amplify localized cytokine secretion at tumor sites. Its approach is designed to provide tissue-localized cytokine amplification to maximize tumor cell killing. EvolveImmune positions its EVs as the first biologic to directly target tumor cells and deliver focused cytokine effects in the tumor microenvironment. The article reports the company completed a $37 million financing round, indicating external investor support for its technology. No operating metrics such as revenue or user counts are provided in the article.

Total raised

$37M

Funding rounds

1

Latest round

Equity

Latest activity

Dec 2023